Intramuscular aripiprazole or haloperidol and transition to oral therapy in patients with agitation associated with schizophrenia: sub-analysis of a double-blind study

References

• Binder RL, McNiel DE. Emergency psychiatry: contemporary practices in managing acutely violent patients in 20 psychiatric emergency rooms. Psychiatr Serv 1999;50:1553–4
   PubMed Web of Science ®Google Scholar
• Pilowsky LS, Ring H, Shine PJ, et al. Rapid tranquillisation. A survey of emergency prescribing in a general psychiatric hospital. Br J Psychiatry 1992;160:831–5
   Google Scholar
• Kunik ME, Yudofsky SC, Silver JM, et al. Pharmacologic approach to management of agitation associated with dementia. J Clin Psychiatry 1994;55(Suppl):13–7
   Google Scholar
• San L, Arranz B, Escobar R. Pharmacological management of acutely agitated schizophrenic patients. Curr Pharm Des 2005;11:2471–7
   PubMedGoogle Scholar
• Kapur S, Arenovich T, Agid O, et al. Evidence for onset of antipsychotic effects within the first 24 hours of treatment. Am J Psychiatry 2005;162:939–46
   PubMed Web of Science ®Google Scholar
• Battaglia J. Pharmacological management of acute agitation. Drugs 2005;65:1207–22
   PubMed Web of Science ®Google Scholar
• Hughes DH, Kleespies PM. Treating aggression in the psychiatric emergency service. J Clin Psychiatry 2003;64:10–5
   PubMed Web of Science ®Google Scholar
• Andrezina R, Josiassen R, Marcus R, et al. Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with IM haloperidol. Psycho-pharmacology 2006;88:281–92
   Google Scholar
• Breier A, Meehan K, Birkett M, et al. A double-blind, placebo-controlled dose–response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Arch Gen Psychiatry 2002;59:441–8
   PubMed Web of Science ®Google Scholar
• Wright P, Meehan K, Birkett M, et al. A comparison of the efficacy and safety of olanzapine versus haloperidol during transition from intramuscular to oral therapy. Clin Ther 2003;25:1420–8
   PubMed Web of Science ®Google Scholar
• Brook S, Lucey JV, Gunn KP. Intramuscular ziprasidone compared with intramuscular haloperidol in the treatment of acute psychosis [Ziprasidone I.M. Study Group]. J Clin Psychiatry 2000;61:933–41
   Google Scholar
• Brook S, Walden J, Benattia I, et al. Ziprasidone and haloperidol in the treatment of acute exacerbation of schizophrenia and schizoaffective disorder: comparison of intramuscular and oral formulations in a 6-week, randomized, blinded-assessment study. Psychopharmacology (Berl) 2005;178:514–23
   PubMed Web of Science ®Google Scholar
• Mendelowitz AJ. The utility of intramuscular ziprasidone in the management of acute psychotic agitation. Ann Clin Psychiatry 2004;16:145–54
   PubMedGoogle Scholar
• Jann MW, Bunt RM. Switching antipsychotic drugs: a pharmacokinetic, pharmacodynamic, and practical perspective. Psychopharmacol Bull 2002;36:22–41
   PubMedGoogle Scholar
• Kane JM, Carson WH, Saha AR, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2002;63:763–71
   PubMed Web of Science ®Google Scholar
• Potkin SG, Saha AR, Kujawa MJ, et al. Aripiprazole, an anti-psychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003;60:681–90
   PubMed Web of Science ®Google Scholar
• Kasper S, Lerman MN, McQuade RD, et al. Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int J Neuropsychopharmacol 2003;6:325–37
   Google Scholar
• Pigott TA, Carson WH, Saha AR, et al. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J Clin Psychiatry 2003;64:1048–56
   PubMed Web of Science ®Google Scholar
• Marder SR, McQuade RD, Stock E, et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res 2003;61:123–36
   PubMed Web of Science ®Google Scholar
• McQuade RD, Stock E, Marcus R, et al. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. J Clin Psychiatry 2004;65:47–56
   PubMed Web of Science ®Google Scholar
• Kostic D, Oren D, Marcus R, et al. Intramuscular aripiprazole and lorazepam vs. placebo for agitation in acute mania. Eur Neuropsychopharmacol 2005;15\(Suppl 3):S510, P3.126
   Google Scholar
• Modell S, Daniel D, Stock E, et al. Intramuscular aripiprazole treatment for acute agitation in patients with psychosis. Int J Neuropsychopharmacol 2004;7(Suppl 1):S417
   Google Scholar
• APA. Diagnostic and statistical manual of mental disorders (DSM-IV), 4th ed. Washington (DC): American Psychiatric Association; 1994
   Google Scholar
• Breier A, Hamilton SH. Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia. Biol Psychiatry 1999;45:403–11
   PubMed Web of Science ®Google Scholar
• Guy W. Clinical Global Impressions (CGI). ECDEU assessment manual for psychopharmacology [US Department of Health, Education, and Welfare Publication (ADM) 76–338]. Rockville (MD): National Institute of Mental Health; 1976. p. 218–22
   Google Scholar
• Battaglia J, Lindborg SR, Alaka K, et al. Calming versus sedative effects of intramuscular olanzapine in agitated patients. Am J Emerg Med 2003;21:192–8
   PubMed Web of Science ®Google Scholar
• Corrigan JD, Bogner JA. Factor structure of the agitated behavior scale. J Clin Exp Neuropsychol 1994;16:386–92
   PubMed Web of Science ®Google Scholar
• Dillenschneider A, Oren D, Marcus R, et al. Comparison of intramuscular aripiprazole and haloperidol with placebo in acutely agitated schizophrenia patients. Eur Neuropsychopharmacol 2005;15\(Supp 3):S509
   Google Scholar
• Wright P, Birkett M, David SR, et al. Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. Am J Psychiatry 2001;158:1149–51
   PubMed Web of Science ®Google Scholar
• Daniel DG, Zimbroff DL, Swift RH, et al. The tolerability of intramuscular ziprasidone and haloperidol treatment and the transition to oral therapy. Int Clin Psychopharmacol 2004;19:9–15
   PubMed Web of Science ®Google Scholar
• Zyprexa, Zyprexa United States package insert. Indianapolis (IN): Eli Lilly and Co; 2005
   Google Scholar
• Geodon, Geodon package insert. New York (NY): Pfizer; 2003
   Google Scholar